

Strategic Report, Report of the Directors and
Financial Statements for the Year Ended 31 December 2021
for
Alpha-Cure Limited

Contents of the Financial Statements
for the Year Ended 31 December 2021

	Page
Company Information	1
Strategic Report	2
Report of the Directors	3
Report of the Independent Auditors	5
Income Statement	9
Other Comprehensive Income	10
Balance Sheet	11
Statement of Changes in Equity	13
Cash Flow Statement	14
Notes to the Cash Flow Statement	15
Notes to the Financial Statements	16

DIRECTORS:

S P Atherstone
S Haines
M A Slater
K Baier

SECRETARY:

M A Slater

REGISTERED OFFICE:

Leonard House
Great Central Way
Woodford Halse
Daventry
Northamptonshire
NN11 3PZ

REGISTERED NUMBER:

03191947 (England and Wales)

AUDITORS:

CED Accountancy Services Limited
Registered Auditors
Chartered Accountants
1 Lucas Bridge Business Park
Old Greens Norton Road
Towcester
Northamptonshire
NN12 8AX

BANKERS:

National Westminster Bank Plc
Grange Park Court
Roman Way
Grange Park
Northampton
NN4 5EA

SOLICITORS:

Howes Percival
Oxford House
Northampton
Northamptonshire
NN1 5PN

Strategic Report
for the Year Ended 31 December 2021

The directors present their strategic report for the year ended 31 December 2021.

REVIEW OF BUSINESS

The directors report that the company has performed well.

We aim to present a balanced and comprehensive review of the development and performance of the company during the year and its position at the year end. Our review is consistent with the size and non-complex nature of the company and is written in the context of the risks and uncertainties we face.

We consider the key performance indicators for the group are those that communicate the financial performance and strength of the group as a whole, these being turnover and gross margin.

Turnover has increased by 10.65%, the gross profit margin has increased by 5.18%, leading to an overall increase in net profit margin for the year of 12.33%.

The continuing development of new products and innovative manufacturing processes, along with improvements made to the usable lives of existing products, have significantly contributed to the group's continued growth and keeps the Alpha-Cure brand at the forefront of the UV and Metal Halide lamp industry.

With our knowledge of the industry and focussed direction of management, we feel confident that the company will be able to maintain our business throughout at least the next year.

PRINCIPAL RISKS AND UNCERTAINTIES

The principal risk identified for future prospects relates to the global economic environment and the recovery from the global Covid-19 pandemic.

Brexit Risk

The principal risk identified for the company's future prospects in previous years was the withdrawal of the UK from the European Union. As of the 1st January 2021 due to the agreements that were made in relation to trading agreements the Company has not seen any major effects.

FINANCIAL KEY PERFORMANCE INDICATORS

The Directors have monitored the progress of the overall company strategy and the individual strategic elements by reference to certain financial key performance indicators.

Turnover: £9,593,218 (2020 - £8,670,189)

Gross profit margin: 42.0% (2020 - 36.9%)

ON BEHALF OF THE BOARD:

M A Slater - Director

31 October 2022

Report of the Directors
for the Year Ended 31 December 2021

The directors present their report with the financial statements of the company for the year ended 31 December 2021.

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of the manufacture of ultra violet curing lamps.

DIVIDENDS

The total distribution of dividends for the year ended 31 December 2021 will be £ 1,869,884 .

DIRECTORS

The directors shown below have held office during the whole of the period from 1 January 2021 to the date of this report.

S P Atherstone
S Haines
M A Slater
K Baier

FINANCIAL INSTRUMENTS

The company uses various financial instruments including cash, trade debtors, and trade creditors that arise directly from the company's operations.

The existence of these financial instruments exposes the company to a number of financial risks, which are described in more detail below.

The main risks arising from the company's financial instruments are liquidity risk, interest rate risk and credit risk. The directors review and agree policies for managing each of these risks and they are summarised below:

LIQUIDITY RISK

The company seeks to manage finance risk by ensuring sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably.

INTEREST RATE RISK

The company finances its operations through a mixture of retained profits and cash balances. Cash is managed to maximise income from interest while avoiding inherent risk.

CREDIT RISK

The company's principle financial assets are cash and trade debtors.

In order to manage credit risk the directors set limits for customers based on a combination of payment history and third party credit references. Credit limits are reviewed by the credit controller on a regular basis in conjunction with debt ageing and collection history.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

Report of the Directors
for the Year Ended 31 December 2021

STATEMENT OF DIRECTORS' RESPONSIBILITIES - continued

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

ON BEHALF OF THE BOARD:

M A Slater - Director

31 October 2022

Opinion

We have audited the financial statements of Alpha-Cure Limited (the 'company') for the year ended 31 December 2021 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on pages three and four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The engagement partner ensured that the engagement team had the appropriate competence, capabilities and skills to identify or recognise non compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation, employment environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above;
- we communicated identified laws and regulations within the audit team who remained alert to instances of non-compliance.

We assessed the susceptibility of the company's financial statements to material misstatement including obtaining an understanding of how fraud might occur, by;

- making enquiries of management as to whether they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud;
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations; and
- understanding the design of the company's remuneration policies.

To address the risk of fraud through management bias and override of controls, we;

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;

In response to the risk of non-compliance with laws and regulations, we designed procedures which included, but were not limited to;

- agreeing financial statement disclosures to underlying supporting documentation;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC and the company's legal advisors.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Alpha-Cure Limited

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Clifford Davidson BSc FCA (Senior Statutory Auditor)
for and on behalf of CED Accountancy Services Limited
Registered Auditors
Chartered Accountants
1 Lucas Bridge Business Park
Old Greens Norton Road
Towcester
Northamptonshire
NN12 8AX

31 October 2022

Income Statement
for the Year Ended 31 December 2021

	Notes	31.12.21 £	£	31.12.20 £	£
TURNOVER			9,593,218		8,670,189
Cost of sales			<u>5,555,087</u>		<u>5,469,657</u>
GROSS PROFIT			4,038,131		3,200,532
Distribution costs		507,830		598,241	
Administrative expenses		<u>1,204,267</u>		<u>1,037,206</u>	
			<u>1,712,097</u>		<u>1,635,447</u>
			2,326,034		1,565,085
Other operating income			<u>4,329</u>		<u>3,771</u>
OPERATING PROFIT	4		2,330,363		1,568,856
Income from shares in group undertakings			<u>609,484</u>		-
			2,939,847		1,568,856
Interest payable and similar expenses	5		<u>30,569</u>		<u>30,421</u>
PROFIT BEFORE TAXATION			2,909,278		1,538,435
Tax on profit	6		<u>317,095</u>		<u>178,271</u>
PROFIT FOR THE FINANCIAL YEAR			<u>2,592,183</u>		<u>1,360,164</u>

Other Comprehensive Income
for the Year Ended 31 December 2021

	Notes	31.12.21 £	31.12.20 £
PROFIT FOR THE YEAR		2,592,183	1,360,164
OTHER COMPREHENSIVE INCOME		-	-
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		<u>2,592,183</u>	<u>1,360,164</u>

Balance Sheet
31 December 2021

	Notes	31.12.21 £	£	31.12.20 £	£
FIXED ASSETS					
Intangible assets	8		1,241		1,529
Tangible assets	9		574,520		613,558
Investments	10		4,814,000		4,814,000
			<u>5,389,761</u>		<u>5,429,087</u>
CURRENT ASSETS					
Stocks	11	1,817,266		1,312,940	
Debtors	12	2,467,602		2,460,571	
Cash at bank		<u>224,610</u>		<u>237,464</u>	
		4,509,478		4,010,975	
CREDITORS					
Amounts falling due within one year	13	<u>6,491,824</u>		<u>6,693,882</u>	
NET CURRENT LIABILITIES			<u>(1,982,346)</u>		<u>(2,682,907)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			3,407,415		2,746,180
CREDITORS					
Amounts falling due after more than one year	14		(25,893)		(81,275)
PROVISIONS FOR LIABILITIES	18		<u>(106,332)</u>		<u>(112,014)</u>
NET ASSETS			<u>3,275,190</u>		<u>2,552,891</u>
CAPITAL AND RESERVES					
Called up share capital	19		104		104
Share premium	20		287,991		287,991
Capital redemption reserve	20		5		5
Retained earnings	20		<u>2,987,090</u>		<u>2,264,791</u>
SHAREHOLDERS' FUNDS			<u>3,275,190</u>		<u>2,552,891</u>

Alpha-Cure Limited (Registered number: 03191947)

Balance Sheet - continued
31 December 2021

The financial statements were approved by the Board of Directors and authorised for issue on 31 October 2022 and were signed on its behalf by:

M A Slater - Director

The notes form part of these financial statements

Statement of Changes in Equity
for the Year Ended 31 December 2021

	Called up share capital £	Retained earnings £	Share premium £	Capital redemption reserve £	Total equity £
Balance at 1 January 2020	104	1,805,027	287,991	5	2,093,127
Changes in equity					
Dividends	-	(900,400)	-	-	(900,400)
Total comprehensive income	-	1,360,164	-	-	1,360,164
Balance at 31 December 2020	104	2,264,791	287,991	5	2,552,891
Changes in equity					
Dividends	-	(1,869,884)	-	-	(1,869,884)
Total comprehensive income	-	2,592,183	-	-	2,592,183
Balance at 31 December 2021	104	2,987,090	287,991	5	3,275,190

The notes form part of these financial statements

Cash Flow Statement
for the Year Ended 31 December 2021

	Notes	31.12.21 £	31.12.20 £
Cash flows from operating activities			
Cash generated from operations	1	1,946,212	1,512,648
Interest paid		(28,728)	(26,308)
Interest element of hire purchase payments paid		(1,841)	(4,113)
Tax paid		(193,815)	(124,389)
Net cash from operating activities		<u>1,721,828</u>	<u>1,357,838</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		(66,274)	(131,876)
Dividends received		609,484	-
Net cash from investing activities		<u>543,210</u>	<u>(131,876)</u>
Cash flows from financing activities			
Loan repayments in year		(30,000)	-
Movement in intercompany loans		(303,862)	118,808
Capital repayments in year		(24,569)	(40,105)
Amount introduced by directors		23,833	40,001
Amount withdrawn by directors		(73,410)	(12,760)
Equity dividends paid		(1,869,884)	(900,400)
Net cash from financing activities		<u>(2,277,892)</u>	<u>(794,456)</u>
(Decrease)/increase in cash and cash equivalents		<u>(12,854)</u>	<u>431,506</u>
Cash and cash equivalents at beginning of year	2	237,464	(194,042)
Cash and cash equivalents at end of year	2	<u>224,610</u>	<u>237,464</u>

The notes form part of these financial statements

Notes to the Cash Flow Statement
for the Year Ended 31 December 2021

1. **RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS**

	31.12.21	31.12.20
	£	£
Profit before taxation	2,909,278	1,538,435
Depreciation charges	105,598	100,197
Finance costs	30,569	30,421
Finance income	(609,484)	-
	<u>2,435,961</u>	<u>1,669,053</u>
Increase in stocks	(504,326)	(27,262)
Decrease/(increase) in trade and other debtors	31,171	(167,349)
(Decrease)/increase in trade and other creditors	(16,594)	38,206
Cash generated from operations	<u>1,946,212</u>	<u>1,512,648</u>

2. **CASH AND CASH EQUIVALENTS**

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2021

	31.12.21	1.1.21
	£	£
Cash and cash equivalents	<u>224,610</u>	<u>237,464</u>

Year ended 31 December 2020

	31.12.20	1.1.20
	£	£
Cash and cash equivalents	237,464	-
Bank overdrafts	-	(194,042)
	<u>237,464</u>	<u>(194,042)</u>

3. **ANALYSIS OF CHANGES IN NET FUNDS**

	At 1.1.21	Cash flow	At 31.12.21
	£	£	£
Net cash			
Cash at bank	<u>237,464</u>	<u>(12,854)</u>	<u>224,610</u>
	<u>237,464</u>	<u>(12,854)</u>	<u>224,610</u>
Debt			
Finance leases	(58,504)	24,569	(33,935)
Debts falling due within 1 year	(32,783)	(1,324)	(34,107)
Debts falling due after 1 year	(57,217)	31,324	(25,893)
	<u>(148,504)</u>	<u>54,569</u>	<u>(93,935)</u>
Total	<u>88,960</u>	<u>41,715</u>	<u>130,675</u>

Notes to the Financial Statements
for the Year Ended 31 December 2021

1. **STATUTORY INFORMATION**

Alpha-Cure Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements

The financial statements contain information about Alpha-Cure Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertakings are included by full consolidation in the consolidated financial statements of its parent, Alpha-Cure Group Limited, Leonard House Great Central Way, Woodford Halse, Daventry, England, NN11 3PZ.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of twenty years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.

Short leasehold	- 15% on cost
Plant and machinery	- 15% on reducing balance
Fixtures and fittings	- 25% on reducing balance

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

2. ACCOUNTING POLICIES - continued

Financial instruments

The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, bank overdrafts, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest rate method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in a case of an out-right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Income Statement.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive if the asset were to be sold at the reporting date.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

2. **ACCOUNTING POLICIES - continued**

Hire purchase and leasing commitments

Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. **EMPLOYEES AND DIRECTORS**

	31.12.21	31.12.20
	£	£
Wages and salaries	1,667,503	1,572,228
Social security costs	150,398	137,078
Other pension costs	110,524	90,165
	<u>1,928,425</u>	<u>1,799,471</u>

The average number of employees during the year was as follows:

	31.12.21	31.12.20
Production	35	32
Sales	11	11
Admin (clerical)	10	9
Technical	1	1
	<u>57</u>	<u>53</u>

	31.12.21	31.12.20
	£	£
Directors' remuneration	138,000	116,923
Directors' pension contributions to money purchase schemes	<u>52,873</u>	<u>40,890</u>

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes	<u>3</u>	<u>3</u>
------------------------	----------	----------

4. **OPERATING PROFIT**

The operating profit is stated after charging:

	31.12.21	31.12.20
	£	£
Depreciation - owned assets	96,883	84,237
Depreciation - assets on hire purchase contracts	8,429	15,671
Patents and licences amortisation	288	288
Auditors' remuneration	<u>9,000</u>	<u>9,000</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

5. INTEREST PAYABLE AND SIMILAR EXPENSES

	31.12.21	31.12.20
	£	£
Bank interest	17,157	19,899
Pension loan interest	4,518	4,048
HMRC interest	7,053	2,361
Hire purchase	1,841	4,113
	<u>30,569</u>	<u>30,421</u>

6. TAXATION

Analysis of the tax charge

The tax charge on the profit for the year was as follows:

	31.12.21	31.12.20
	£	£
Current tax:		
UK corporation tax	368,116	212,482
Prior year over/underprovision	(45,339)	(42,277)
Total current tax	<u>322,777</u>	<u>170,205</u>
Deferred tax	(5,682)	8,066
Tax on profit	<u>317,095</u>	<u>178,271</u>

Reconciliation of total tax charge included in profit and loss

The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

	31.12.21	31.12.20
	£	£
Profit before tax	<u>2,909,278</u>	<u>1,538,435</u>
Profit multiplied by the standard rate of corporation tax in the UK of 19% (2020 - 19%)	552,763	292,303
Effects of:		
Expenses not deductible for tax purposes	2,720	1,822
Income not taxable for tax purposes	(115,802)	-
Capital allowances in excess of depreciation	-	(6,643)
Depreciation in excess of capital allowances	3,435	-
Adjustments to tax charge in respect of previous periods in prior year	(45,339)	(42,277)
R&D/Patent Box enhanced deduction estimate	(75,000)	(75,000)
Deferred tax	(5,682)	8,066
Total tax charge	<u>317,095</u>	<u>178,271</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 20217. **DIVIDENDS**

	31.12.21 £	31.12.20 £
Ordinary A shares of £1 each		
Interim	<u>1,869,884</u>	<u>900,400</u>

8. **INTANGIBLE FIXED ASSETS**

	Patents and licences £
COST	
At 1 January 2021	
and 31 December 2021	<u>5,727</u>
AMORTISATION	
At 1 January 2021	4,198
Amortisation for year	288
At 31 December 2021	<u>4,486</u>
NET BOOK VALUE	
At 31 December 2021	<u>1,241</u>
At 31 December 2020	<u>1,529</u>

9. **TANGIBLE FIXED ASSETS**

	Short leasehold £	Plant and machinery £	Fixtures and fittings £	Totals £
COST				
At 1 January 2021	114,894	1,405,425	529,794	2,050,113
Additions	-	61,104	5,170	66,274
At 31 December 2021	<u>114,894</u>	<u>1,466,529</u>	<u>534,964</u>	<u>2,116,387</u>
DEPRECIATION				
At 1 January 2021	78,395	915,082	443,078	1,436,555
Charge for year	15,963	67,083	22,266	105,312
At 31 December 2021	<u>94,358</u>	<u>982,165</u>	<u>465,344</u>	<u>1,541,867</u>
NET BOOK VALUE				
At 31 December 2021	<u>20,536</u>	<u>484,364</u>	<u>69,620</u>	<u>574,520</u>
At 31 December 2020	<u>36,499</u>	<u>490,343</u>	<u>86,716</u>	<u>613,558</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

9. **TANGIBLE FIXED ASSETS - continued**

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

	Plant and machinery £
COST	
At 1 January 2021	104,223
Transfer to ownership	<u>(26,450)</u>
At 31 December 2021	<u>77,773</u>
DEPRECIATION	
At 1 January 2021	39,980
Charge for year	8,429
Transfer to ownership	<u>(14,714)</u>
At 31 December 2021	<u>33,695</u>
NET BOOK VALUE	
At 31 December 2021	<u>44,078</u>
At 31 December 2020	<u>64,243</u>

10. **FIXED ASSET INVESTMENTS**

	Shares in group undertakings £
COST	
At 1 January 2021 and 31 December 2021	<u>4,814,000</u>
NET BOOK VALUE	
At 31 December 2021	<u>4,814,000</u>
At 31 December 2020	<u>4,814,000</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

10. **FIXED ASSET INVESTMENTS - continued**

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Alpha-Cure Asia Limited

Registered office: Factory No.2, Qingpu Export Processing Zone, Qingpu, 201707, Shanghai, China

Nature of business: Manufacture and sale of UV and Metal Halide lamps

	%		
Class of shares:	holding		
Ordinary	75.00	31.12.21	31.12.20
		£	£
Aggregate capital and reserves		5,639,176	6,471,649
Loss for the year		(175,767)	(311,760)

Alpha-Cure Asia Limited is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited.

Alpha-Cure Deutschland GmbH

Registered office: Von-Siemens-Straße 5, 48346 Ostbevern, Deutschland, 48165 Ostbevern, Germany

Nature of business: Sale of UV and Metal Halide lamps

	%		
Class of shares:	holding		
Ordinary	100.00	31.12.21	31.12.20
		£	£
Aggregate capital and reserves		319,243	330,855
Profit for the year		11,580	19,099

Alpha-Cure (Jiangsu) Co. LTD

Registered office: 1360 Nanyuan West Road, Qidong Economic Development Zone, Qidong, Jiangsu 226200, China

Nature of business: Manufacture and sale of UV and Metal Halide lamps

	%		
Class of shares:	holding		
Ordinary	75.00	31.12.21	31.12.20
		£	£
Aggregate capital and reserves		6,284,886	5,630,417
Profit for the year		1,004,193	784,687

Alpha-Cure (Jiangsu) Co. LTD is a 100% subsidiary of Alpha-Cure Asia Limited, which is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

10. **FIXED ASSET INVESTMENTS - continued**

Alpha Cure Australia PTY LTD

Registered office: 27 Ashburton Avenue, West Lakes Shore, SA 5020 Australia

Nature of business: Sale of UV and Metal Halide lamps

	% holding		
Class of shares:			
Ordinary	100.00	30.6.21	30.6.20
		£	£
Aggregate capital and reserves		24,861	15,693
Profit/(loss) for the year		<u>2,691</u>	<u>(4,520)</u>

Alpha-Cure Holdings Limited

Registered office: Leonard House Great Central Way, Woodford Halse, Daventry, England, NN11 3PZ

Nature of business: Holding Company

	% holding		
Class of shares:			
Ordinary	100.00	31.12.21	31.12.20
		£	£
Aggregate capital and reserves		470,314	432,082
Profit for the year		<u>647,716</u>	<u>41,197</u>

Associated company

Alpha-Cure France Limited

Registered office: ZA Le Messac, 37240 Bossee, France

Nature of business: Sale of UV and Metal Halide lamps

	% holding		
Class of shares:			
Ordinary	49.00	31.12.21	31.12.20
		£	£
Aggregate capital and reserves		438,440	410,403
Profit for the year		<u>183,763</u>	<u>118,468</u>

11. **STOCKS**

		31.12.21	31.12.20
		£	£
Stocks		<u>1,817,266</u>	<u>1,312,940</u>

The Company use the methodology of FIFO to value their stock.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

12. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.21	31.12.20
	£	£
Trade debtors	1,548,083	1,566,819
Amounts owed by group undertakings	804,794	756,763
Other debtors	8,160	7,952
Directors' current accounts	56,164	66,587
Tax	25,983	25,389
VAT	12,809	24,300
Prepayments	11,609	12,761
	<u>2,467,602</u>	<u>2,460,571</u>

13. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.21	31.12.20
	£	£
Other loans (see note 15)	34,107	32,783
Hire purchase contracts (see note 16)	33,935	34,446
Trade creditors	72,432	9,032
Amounts owed to group undertakings	5,481,733	5,737,566
Tax	542,241	412,685
Social security and other taxes	44,919	73,329
Other creditors	8,397	6,506
Directors' current accounts	11,583	71,583
Accrued expenses	262,477	315,952
	<u>6,491,824</u>	<u>6,693,882</u>

14. **CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	31.12.21	31.12.20
	£	£
Other loans (see note 15)	25,893	57,217
Hire purchase contracts (see note 16)	-	24,058
	<u>25,893</u>	<u>81,275</u>

15. **LOANS**

An analysis of the maturity of loans is given below:

	31.12.21	31.12.20
	£	£
Amounts falling due within one year or on demand:		
Other loans	<u>34,107</u>	<u>32,783</u>
Amounts falling due between two and five years:		
Other loans - instalments due		
2 - 5 years	<u>25,893</u>	<u>57,217</u>
	<u>25,893</u>	<u>57,217</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

16. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

	Hire purchase contracts	
	31.12.21	31.12.20
	£	£
Net obligations repayable:		
Within one year	33,935	34,446
Between one and five years	-	24,058
	<u>33,935</u>	<u>58,504</u>

	Non-cancellable operating leases	
	31.12.21	31.12.20
	£	£
Within one year	80,500	80,500
Between one and five years	241,500	322,000
	<u>322,000</u>	<u>402,500</u>

17. SECURED DEBTS

The following secured debts are included within creditors:

	31.12.21	31.12.20
	£	£
Other loans	60,000	90,000
Hire purchase contracts	33,935	58,504
	<u>93,935</u>	<u>148,504</u>

National Westminster Bank Plc hold a debenture dated 2 January 2007 including a first fixed charge on book debts and other debts.

All finance lease and hire purchase contracts are secured on assets financed (see note 6).

18. PROVISIONS FOR LIABILITIES

	31.12.21	31.12.20
	£	£
Deferred tax		
Accelerated capital allowances	<u>106,332</u>	<u>112,014</u>

	Deferred tax
	£
Balance at 1 January 2021	112,014
Accelerated capital allowances	(5,682)
Balance at 31 December 2021	<u>106,332</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2021

19. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:		Nominal value:	31.12.21	31.12.20
Number:	Class:		£	£
26	Ordinary A	£1	26	26
78	Ordinary B	£1	78	78
			<u>104</u>	<u>104</u>

20. RESERVES

	Retained earnings £	Share premium £	Capital redemption reserve £	Totals £
At 1 January 2021	2,264,791	287,991	5	2,552,787
Profit for the year	2,592,183			2,592,183
Dividends	(1,869,884)			(1,869,884)
At 31 December 2021	<u>2,987,090</u>	<u>287,991</u>	<u>5</u>	<u>3,275,086</u>

21. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 December 2021 and 31 December 2020:

	31.12.21 £	31.12.20 £
S P Atherstone		
Balance outstanding at start of year	24,355	24,355
Amounts advanced	1,826	-
Amounts repaid	-	-
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>26,181</u>	<u>24,355</u>
S Haines		
Balance outstanding at start of year	1,175	1,175
Amounts repaid	-	-
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>1,175</u>	<u>1,175</u>
M A Slater		
Balance outstanding at start of year	41,058	38,299
Amounts advanced	-	2,759
Amounts repaid	(12,250)	-
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>28,808</u>	<u>41,058</u>

21. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES - continued

Interest rate charged on Directors' Loans is 0%.

22. RELATED PARTY DISCLOSURES

During the year the company traded with other companies within the group.,

Balances outstanding at the year end with group companies are:

Owed to Alpha-Cure Limited:

Alpha-Cure Asia (Subsidiary) - £48,030

Alpha-Cure Australia (Subsidiary) - £8,504

Owed by Alpha-Cure Limited:

Alpha-Cure Asia (Subsidiary) - £491,852

Loans outstanding at the year end with group companies are:

Owed to Alpha-Cure Limited:

Alpha-Cure Holdings Ltd (Subsidiary) - £292,882

Owed by Alpha-Cure Limited:

Alpha-Cure Group Ltd (Parent Company) - £4,526,000

Alpha-Cure RBS (Pension Scheme) - £60,000

Sales to related parties in the year were:

Alpha-Cure Asia (Subsidiary) - £721,226

Alpha-Cure Australia (Subsidiary) - £55,698

Alpha-Cure Deutschland (Subsidiary) - £273,816

Purchases from related parties in the year were:

Alpha-Cure Asia (Subsidiary) - £3,337,564

Alpha-Cure RBS (Pension Scheme) - £96,600

Entities with control, joint control or significant influence over the entity

	31.12.21	31.12.20
	£	£
Dividends	<u>1,869,884</u>	<u>900,400</u>

During the year, a total of key management personnel compensation of £ 281,506 (2020 - £ 239,459) was paid.

23. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Alpha-Cure Group Limited (a Company registered in England and Wales) by virtue of its majority shareholding.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.